论文部分内容阅读
目的观察普罗布考联合瑞舒伐他汀治疗脑梗死伴颈动脉斑块的临床效果。方法收集2013年7月-2015年6月医院收治的脑梗死伴颈动脉斑块患者113例,根据随机、单盲、平行对照设计原则分为对照组55例和观察组58例,对照组给予普罗布考治疗,观察组在此基础上联合使用瑞舒伐他汀治疗,将2组患者治疗后的颈动脉内膜中层厚度、血清超敏C反应蛋白(hs-CRP)以及脂蛋白水平进行观察和对比。结果观察组治疗后的颈动脉内膜中层厚度为(1.0±0.1)mm明显低于对照组的(1.2±0.3)mm,观察组血清hs-CRP水平为(2.8±0.6)mg/L显著低于对照组的(6.3±1.2)mg/L,观察组脂蛋白水平为(15.4±3.2)U/m L显著低于对照组的(25.9±6.3)U/m L,差异均有统计学意义(P<0.05)。结论在脑梗死伴颈动脉斑块患者的治疗过程中,普罗布考联合瑞舒伐他汀能够使颈动脉粥样硬化斑块得到稳定,优化炎症因子,降低血脂水平,患者预后良好,值得推广应用。
Objective To observe the clinical efficacy of probucol combined with rosuvastatin in treating cerebral infarction with carotid artery plaque. Methods A total of 113 patients with cerebral infarction and carotid plaque admitted from July 2013 to June 2015 were randomly divided into control group (n = 55) and observation group (n = 58) according to the randomized, single-blind and parallel control design principles Probucol treatment, the observation group on the basis of combination of rosuvastatin treatment, the two groups of patients after treatment of carotid intima-media thickness, serum hs-CRP and lipoprotein levels were observed And contrast. Results The carotid intima-media thickness in the observation group was (1.0 ± 0.1) mm lower than that in the control group (1.2 ± 0.3) mm, and the serum hs-CRP level in the observation group was significantly lower than (2.8 ± 0.6) mg / L (6.3 ± 1.2) mg / L in the control group, (15.4 ± 3.2) U / m L in the observation group was significantly lower than that of the control group (25.9 ± 6.3) U / m L, the differences were statistically significant (P <0.05). Conclusions Probucol combined with rosuvastatin can stabilize the carotid atherosclerosis plaque during the treatment of patients with cerebral infarction and carotid plaque. Optimizing the inflammatory factors and decreasing the blood lipid level, the patients with good prognosis are worth popularizing. .